<DOC>
	<DOCNO>NCT01013025</DOCNO>
	<brief_summary>The main study objective collect implant retrieval information 10 patient use Vantas® , 50 mg histrelin implant . Patients identify difficult locate non-palpable implant enrol . Sites adhere instruction Package Insert , include specialized investigation ultrasound , CT , MRI , use location removal implant .</brief_summary>
	<brief_title>Vantas Implant Retrieval Study</brief_title>
	<detailed_description>Up 50 center use Vantas , recently approve histrelin implant part urology practice treat patient advanced prostate cancer , identify participation Phase IV post-marketing trial . Up 10 patient implanted Vantas participating center , difficult locate non-palpable implant time removal , enrol trial . A Screening Visit conduct consent patient collect basic medical safety information patient participation . Upon patient enrollment , three subsequent Visits ( Visits 1 , 2 , 3 ) conduct ( within 2 week Screening Visit ) . The investigator locate remove implant follow instruction provide protocol . Methods location implant include ultrasound , CT , MRI procedures . The visit implant successfully locate remove final study visit patient . Upon successful retrieval implant determination , per Study Instructions , implant located/removed , study complete patient . No information collect re-implantation new implant . Safety monitor throughout two week study . Blood sample testosterone PSA collect Screening Visit . The implant remove patient return Indevus Pharmaceuticals analysis .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Were male patient adenocarcinoma prostate ; Were age 45 year old ; Had receive Vantas® implant ; Had difficult locate nonpalpable implant time implant retrieval ; Had ability undergo ultrasound , and/or CT , and/or MRI within two week Screening Visit ; Voluntarily provide Informed Consent prior performance studyspecific procedure . Major medical psychiatric illness would interfere return visit ; patient suitable ( e.g. , noncompliance history ) study opinion Investigator Sponsor ; Participated clinical trial investigational agent within 30 day prior Screening Visit ( unless enrol Protocol 301 Extension ) .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>implant retrieval</keyword>
</DOC>